Skip to main content

Table 2 Median values (interquartile spacing) for comparison between lymphocyte count, lymphocyte subsets, and dendritic cells before the treatment

From: Effect of immune-modulating metronomic capecitabine as an adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma

Group

Lymphocyte count

CD4+

CD8+

CD28 + CD4+

Activated CD4+

CD28 + CD8+

Activated CD8+

CD4/CD8 ratio

CD3+

PDCs

MDCs

Experimental group

1.70 × 109(1.33–2.04 × 109)

35.05(19.34–50.60)

21.89(12.90-36.94)

33.66(15.61–49.37)

1.15(0.61–2.31)

12.81(8.27–21.55)

1.05(0.27–1.93)

1.53(0.82–3.49)

64.10(53.85–74.83)

2.50(1.20–5.90)

5.75(2.34–10.20)

Control group

1.91 × 109(1.42–2.39 × 109)

33.91(24.25–45.99)

16.92(9.88–33.70)

30.35(21.17–44.46)

1.51(0.40–4.10)

12.04(7.78–16.26)

0.67(0.20–12.20)

1.74(0.74–4.21)

60.26(44.14–70.18)

2.33(0.40–2.90)

5.15(1.78-8.00)

Z

1.199

-0.58

-3.38

-1.60

0.40

-1.13

-0.02

0.86

-5.12

0.18

-0.39

P

0.376

0.84

0.19

0.64

0.21

0.29

1.00

0.40

0.05

0.24

0.64